| Carrie Deluca, | |
|
2200 Crow Ln Ste 201, Myrtle Beach, SC 29577-1663 | |
| (843) 848-5001 | |
| Not Available |
| Full Name | Carrie Deluca |
|---|---|
| Gender | Female |
| Speciality | Occupational Therapy |
| Experience | 20 Years |
| Location | 2200 Crow Ln Ste 201, Myrtle Beach, South Carolina |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1093820235 | NPI | - | NPPES |
| 3083 | Other | SC | LICENSE # |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225X00000X | Occupational Therapist | (* (Not Available)) | Secondary |
| 225X00000X | Occupational Therapist | 3083 (South Carolina) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Georgetown Physician Associates, Llc | 2365697398 | 149 |
News Archive
Oncolytics Biotech Inc. announced today that it has completed enrollment in the first, 80 patient stage of its Phase III clinical trial examining REOLYSIN in combination with paclitaxel and carboplatin in patients with platinum-refractory head and neck cancers (REO 018).
Atypical antipsychotic drugs benefit patients with acute schizophrenia across the full spectrum of symptom severity, as well as highly symptomatic patients with predominantly negative symptoms, suggests a meta-analysis published in JAMA Psychiatry.
ZOLL Medical Corporation, a manufacturer of medical devices and related software solutions, announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration to market and begin distribution of the new Propaq® MD Monitor/Defibrillator that was developed specifically to meet the special needs of military customers and air medical operations worldwide. Development of this product was a joint undertaking between the Department of Defense and a cooperative arrangement between Welch Allyn and ZOLL.
A protein first shown to function in the liver plays a crucial role in pregnancy in mice and has a key role in the human menstrual cycle, according to researchers at the University of Montreal. Mice that were genetically engineered not to produce the liver receptor homolog-1 (Lrh-1) molecule were unable to create the uterine conditions necessary for establishing and sustaining pregnancy, resulting in the formation of defective placentas.
Anchor Therapeutics today announced that it has successfully completed the first stage of its collaboration and license agreement with Ortho-McNeil-Janssen Pharmaceuticals.
› Verified 5 days ago
| Provider Name | Georgetown Physician Associates, Llc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1235475930 PECOS PAC ID: 2365697398 Enrollment ID: O20130225000067 |
News Archive
Oncolytics Biotech Inc. announced today that it has completed enrollment in the first, 80 patient stage of its Phase III clinical trial examining REOLYSIN in combination with paclitaxel and carboplatin in patients with platinum-refractory head and neck cancers (REO 018).
Atypical antipsychotic drugs benefit patients with acute schizophrenia across the full spectrum of symptom severity, as well as highly symptomatic patients with predominantly negative symptoms, suggests a meta-analysis published in JAMA Psychiatry.
ZOLL Medical Corporation, a manufacturer of medical devices and related software solutions, announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration to market and begin distribution of the new Propaq® MD Monitor/Defibrillator that was developed specifically to meet the special needs of military customers and air medical operations worldwide. Development of this product was a joint undertaking between the Department of Defense and a cooperative arrangement between Welch Allyn and ZOLL.
A protein first shown to function in the liver plays a crucial role in pregnancy in mice and has a key role in the human menstrual cycle, according to researchers at the University of Montreal. Mice that were genetically engineered not to produce the liver receptor homolog-1 (Lrh-1) molecule were unable to create the uterine conditions necessary for establishing and sustaining pregnancy, resulting in the formation of defective placentas.
Anchor Therapeutics today announced that it has successfully completed the first stage of its collaboration and license agreement with Ortho-McNeil-Janssen Pharmaceuticals.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Carrie Deluca, Po Box 421718, Georgetown, SC 29442-4203 Ph: (843) 652-8226 | Carrie Deluca, 2200 Crow Ln Ste 201, Myrtle Beach, SC 29577-1663 Ph: (843) 848-5001 |
News Archive
Oncolytics Biotech Inc. announced today that it has completed enrollment in the first, 80 patient stage of its Phase III clinical trial examining REOLYSIN in combination with paclitaxel and carboplatin in patients with platinum-refractory head and neck cancers (REO 018).
Atypical antipsychotic drugs benefit patients with acute schizophrenia across the full spectrum of symptom severity, as well as highly symptomatic patients with predominantly negative symptoms, suggests a meta-analysis published in JAMA Psychiatry.
ZOLL Medical Corporation, a manufacturer of medical devices and related software solutions, announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration to market and begin distribution of the new Propaq® MD Monitor/Defibrillator that was developed specifically to meet the special needs of military customers and air medical operations worldwide. Development of this product was a joint undertaking between the Department of Defense and a cooperative arrangement between Welch Allyn and ZOLL.
A protein first shown to function in the liver plays a crucial role in pregnancy in mice and has a key role in the human menstrual cycle, according to researchers at the University of Montreal. Mice that were genetically engineered not to produce the liver receptor homolog-1 (Lrh-1) molecule were unable to create the uterine conditions necessary for establishing and sustaining pregnancy, resulting in the formation of defective placentas.
Anchor Therapeutics today announced that it has successfully completed the first stage of its collaboration and license agreement with Ortho-McNeil-Janssen Pharmaceuticals.
› Verified 5 days ago
Kel Z Gaskin Prock, MSR, OTR L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 3603 Kingsley Dr, Myrtle Beach, SC 29588 Phone: 843-424-5450 | |
Shannon Southerland, Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 5000 Highway 17 Byp S, Myrtle Beach, SC 29588 Phone: 843-252-0033 | |
Dorothy Gregory, Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 3620 Happy Woods Ct, Myrtle Beach, SC 29588 Phone: 843-293-2246 | |
Jacqueline Gibbons, Occupational Therapist Medicare: Medicare Enrolled Practice Location: 3799 Cape Landing Cir Apt C, Myrtle Beach, SC 29588 Phone: 845-313-2012 | |
Gabrielle Marrero, Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 4761 Highway 501 Ste 1, Myrtle Beach, SC 29579 Phone: 843-455-7505 | |
Alayna K Cline, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 109 Mountain Ash Ln Unit C, Myrtle Beach, SC 29579 Phone: 843-575-8768 |